CR

CreoSG Co.,Ltd.

Offers IT solutions to financial institutions and develops vaccines for HIV and coronaviruses.

040350 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
서울특별시 강남구 테헤란로13길 31-1 4층(역삼동, 일리빌딩), 강남구
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

CreoSG Co., Ltd. operates as a diversified company with two primary business segments: IT solutions and biotechnology. The IT division specializes in developing and supplying software and next-generation systems for financial institutions, offering services that include application development, IT outsourcing, and infrastructure management. Concurrently, the company has a significant focus on the biotechnology sector, primarily conducting vaccine research and development. This division leverages a proprietary recombinant VSV (Vesicular Stomatitis Virus) vector platform technology to develop novel vaccines, with key projects targeting HIV/AIDS and various coronaviruses.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for CreoSG Co.,Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-19 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제3자배정-소액공모)
Korean 7.5 KB
2025-09-19 00:00
Share Issue/Capital Change
소액공모실적보고서
Korean 29.0 KB
2025-09-18 00:00
Major Shareholding Notification
최대주주변경을수반하는주식담보제공계약해제ㆍ취소등
Korean 19.8 KB
2025-09-11 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 51.0 KB
2025-09-11 00:00
Share Issue/Capital Change
소액공모공시서류(지분증권)
Korean 2.2 MB
2025-09-10 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 60.5 KB
2025-09-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 163.4 KB
2025-09-03 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 39.7 KB
2025-09-01 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득 (제22회차)
Korean 9.3 KB
2025-08-29 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 44.9 KB

Automate Your Workflow. Get a real-time feed of all CreoSG Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for CreoSG Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Trainers´ House Oyj Logo
Consulting & coaching firm driving growth via leadership, sales & strategy execution.
Finland TRH1V
TRAJANO Logo
Provides strategic consulting and innovative business solutions.
Spain YTRA
Transgene Logo
Developing viral immunotherapies like vaccines and oncolytic viruses to treat solid tumors.
France TNG
TRANS GENIC GROUP INC. Logo
Offers drug discovery CRO services (gene editing, trials) and business investment/consulting.
Japan 2342
True Data Inc. Logo
A big data platform offering consumer purchasing analytics from Japan's largest ID-POS data network.
Japan 4416
Tsubota Laboratory Incorporated Logo
Developing pharmaceuticals and medical devices for ophthalmic and brain diseases.
Japan 4890
Tvardi Therapeutics Inc. Logo
Clinical-stage biopharma developing oral STAT3 inhibitors for fibrotic diseases.
United States of America TVRD
TWOSTONE&Sons Inc. Logo
An engineer platform providing IT talent and marketing services for corporate digital transformation.
Japan 7352
UJU Holding Limited Logo
AI-driven, full-link short-video marketing solutions for enterprises in China.
Hong Kong 1948
unerry,Inc. Logo
Transforms location data into actionable insights for retail and public sectors using AI.
Japan 5034

Talk to a Data Expert

Have a question? We'll get back to you promptly.